C50.612: Malignant neoplasm of axillary tail of left female breast
C50.612, malignant neoplasm of axillary tail of left female breast, is listed as a covered diagnosis in 22 Medicare billing and coding articles that apply to 123 HCPCS Level II codes, including C8903 (Magnetic resonance imaging with contrast, breast; unilateral), C8905 (Magnetic resonance imaging without contrast followed by…), C8906 (Magnetic resonance imaging with contrast, breast; bilateral). 10 of these codes have a 2026 DMEPOS fee schedule amount; L8035 pays $4,403.11 to $5,283.69 depending on the state. The articles come from 4 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with C50.612 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| C8903 | Magnetic resonance imaging with contrast, breast; unilateral | Special coverage instructions apply | — | 2 |
| C8905 | Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral | Special coverage instructions apply | — | 2 |
| C8906 | Magnetic resonance imaging with contrast, breast; bilateral | Special coverage instructions apply | — | 2 |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | Special coverage instructions apply | — | 2 |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Special coverage instructions apply | — | 2 |
| J1952 | Leuprolide injectable, camcevi, 1 mg | Carrier judgment | — | 2 |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Special coverage instructions apply | — | 2 |
| J1954 | Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg | Carrier judgment | — | 2 |
| J9202 | Goserelin acetate implant, per 3.6 mg | Special coverage instructions apply | — | 2 |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | Special coverage instructions apply | — | 2 |
| J9219 | Leuprolide acetate implant, 65 mg | Special coverage instructions apply | — | 2 |
| J9225 | Histrelin implant (vantas), 50 mg | Special coverage instructions apply | — | 2 |
| L8035 | Custom breast prosthesis, post mastectomy, molded to patient model, any type | Special coverage instructions apply | $4,403.11–$5,283.69 | 1 |
| L8002 | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral, any size, any type | Special coverage instructions apply | $198.27–$218.12 | 1 |
| L8001 | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral, any size, any type | Special coverage instructions apply | $150.77–$165.83 | 1 |
| L8015 | External breast prosthesis garment, with mastectomy form, post mastectomy | Special coverage instructions apply | $72.05–$86.41 | 1 |
| L8000 | Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type | Special coverage instructions apply | $44.70–$78.16 | 1 |
| A4280 | Adhesive skin support attachment for use with external breast prosthesis, each | Carrier judgment | $7.38–$8.13 | 1 |
| Q2028 | Injection, sculptra, 0.5 mg | Special coverage instructions apply | — | 2 |
| G0429 | Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy) | Carrier judgment | — | 2 |
| Q2026 | Injection, radiesse, 0.1 ml | Special coverage instructions apply | — | 2 |
| C9726 | Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure | Special coverage instructions apply | — | 1 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Special coverage instructions apply | — | 3 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Special coverage instructions apply | — | 3 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Special coverage instructions apply | — | 3 |
98 more codes are listed. See every code with payment by region in Caduvo.
Medicare policy articles listing C50.612
- A52478: External Breast Prostheses - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 6 Level II codes). LCD with the same title: L33317
- A56684: Billing and Coding: Intraoperative Radiation Therapy (Palmetto GBA (MAC - Part A, MAC - Part B); 1 Level II codes). LCD with the same title: L37779
- A52849: Billing and Coding: Breast Imaging: Breast Echography (Sonography)/Breast MRI/Ductography (Wellpoint Federal (MAC - Part A, MAC - Part B); 4 Level II codes). LCD with the same title: L33585
- A56448: Billing and Coding: Breast Imaging Mammography/Breast Echography (Sonography)/Breast MRI/Ductography (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 5 Level II codes). LCD with the same title: L33950
- A59160: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Palmetto GBA (MAC - Part A, MAC - Part B); 8 Level II codes). LCD with the same title: L39387
- A52453: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes). LCD with the same title: L39387
- A59299: Billing and Coding: Cosmetic and Reconstructive Surgery (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L33428, L35090, L38914, L39051
- A58774: Billing and Coding: Cosmetic and Reconstructive Surgery (WPS Insurance Corporation (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L33428, L35090, L38914, L39051
- A56907: Billing and Coding: Bisphosphonate Drug Therapy (WPS Insurance Corporation (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L34648
- A52399: Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes)
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 8 Level II codes)
- A52450: Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™) (Wellpoint Federal (MAC - Part A, MAC - Part B); 2 Level II codes)
- A59350: Billing and Coding: Radiation Therapies (Palmetto GBA (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L39553
- A58982: Billing and Coding: Erythropoiesis Stimulating Agents (Palmetto GBA (MAC - Part A, MAC - Part B); 9 Level II codes). LCD with the same title: L39237
- A54768: Billing and Coding: Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning- MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy (Palmetto GBA (MAC - Part A, MAC - Part B); 5 Level II codes)
7 more articles list C50.612.
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other C50 diagnoses (Malignant neoplasm of breast)
- C50.611 — Malignant neoplasm of axillary tail of right female breast
- C50.619 — Malignant neoplasm of axillary tail of unspecified female breast
- C50.621 — Malignant neoplasm of axillary tail of right male breast
- C50.622 — Malignant neoplasm of axillary tail of left male breast
- C50.629 — Malignant neoplasm of axillary tail of unspecified male breast
- C50.011 — Malignant neoplasm of nipple and areola, right female breast
- C50.012 — Malignant neoplasm of nipple and areola, left female breast
- C50.019 — Malignant neoplasm of nipple and areola, unspecified female breast
- C50.021 — Malignant neoplasm of nipple and areola, right male breast
- C50.022 — Malignant neoplasm of nipple and areola, left male breast
- C50.029 — Malignant neoplasm of nipple and areola, unspecified male breast
- C50.111 — Malignant neoplasm of central portion of right female breast
- C50.112 — Malignant neoplasm of central portion of left female breast
- C50.119 — Malignant neoplasm of central portion of unspecified female breast
- C50.121 — Malignant neoplasm of central portion of right male breast
- C50.122 — Malignant neoplasm of central portion of left male breast
- C50.129 — Malignant neoplasm of central portion of unspecified male breast
- C50.211 — Malignant neoplasm of upper-inner quadrant of right female breast
- C50.212 — Malignant neoplasm of upper-inner quadrant of left female breast
- C50.219 — Malignant neoplasm of upper-inner quadrant of unspecified female…
- C50.221 — Malignant neoplasm of upper-inner quadrant of right male breast
- C50.222 — Malignant neoplasm of upper-inner quadrant of left male breast
- C50.229 — Malignant neoplasm of upper-inner quadrant of unspecified male breast
- C50.311 — Malignant neoplasm of lower-inner quadrant of right female breast
- C50.312 — Malignant neoplasm of lower-inner quadrant of left female breast
- C50.319 — Malignant neoplasm of lower-inner quadrant of unspecified female…
- C50.321 — Malignant neoplasm of lower-inner quadrant of right male breast
- C50.322 — Malignant neoplasm of lower-inner quadrant of left male breast
- C50.329 — Malignant neoplasm of lower-inner quadrant of unspecified male breast
- C50.411 — Malignant neoplasm of upper-outer quadrant of right female breast
Frequently asked questions
Does Medicare cover C50.612 (Malignant neoplasm of axillary tail of left female breast)?
Medicare covers items and services, not diagnoses. 22 Medicare billing and coding articles list C50.612 as a covered diagnosis for 123 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 C50.612?
The Level II codes from the policies most specific to this diagnosis are C8903 (Magnetic resonance imaging with contrast, breast; unilateral, 2 articles); C8905 (Magnetic resonance imaging without contrast followed by…, 2 articles); C8906 (Magnetic resonance imaging with contrast, breast; bilateral, 2 articles); C8908 (Magnetic resonance imaging without contrast followed by…, 2 articles); J9217 (Leuprolide acetate (for depot suspension), 7.5 mg, 2 articles). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with C50.612?
Under the 2026 DMEPOS fee schedule (non-rural state fees): L8035 $4,403.11 to $5,283.69; L8002 $198.27 to $218.12; L8001 $150.77 to $165.83; L8015 $72.05 to $86.41. Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list C50.612?
A52478 (External Breast Prostheses - Policy Article); A56684 (Billing and Coding: Intraoperative Radiation Therapy); A52849 (Billing and Coding: Breast Imaging: Breast Echography (Sonography)/Breast MRI/Ductography), and 19 more articles.
What is ICD-10-CM code C50.612?
C50.612 is the ICD-10-CM code for malignant neoplasm of axillary tail of left female breast, in category C50 (Malignant neoplasm of breast), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under C8903
- Watch C8903 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C8903
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.